发布于: 修改于:雪球转发：0回复：2喜欢：1

$信立泰(SZ002294)$ DelveInsight 的《2024 年晚期肾细胞癌管线洞察》报告提供了有关晚期肾细胞癌管线格局中 50+ 家公司和 60+ 管线药物的全面见解。它涵盖了在研药物概况，包括临床和非临床阶段产品。它还涵盖了按产品类型、阶段、给药途径和分子类型进行的治疗评估。它进一步突出了该领域中不活跃的管道产品。

晚期肾细胞癌管线报告的主要内容 * 2024 年 7 月：- Ipsen- 卡博替尼作为二线治疗不可切除的局部晚期受试者的 II 期、多中心、开放标签研究或具有透明细胞成分的转移性肾细胞癌，在接受检查点抑制剂一线治疗后进展。本研究的总体目标是评估卡博替尼作为二线治疗在具有透明细胞成分的不可切除、局部晚期或转移性 RCC 受试者中的疗效和安全性，这些受试者在先前检查点抑制剂 （CPI） 治疗后进展伊匹木单抗和纳武利尤单抗联合或 CPI 联合血管内皮生长因子 （VEGF） 靶向治疗。
* 2024 年 6 月：- 百时美施贵宝 - BMS-986315 作为单一疗法以及与纳武利尤单抗或西妥昔单抗联合治疗晚期实体瘤参与者的 1/2 期研究。本研究的目的是评估 BMS-986315 单独使用和联合纳武利尤单抗或西妥昔单抗治疗晚期实体瘤参与者。
* DelveInsight 的晚期肾细胞癌管线报告描绘了一个强大的空间，有 50+ 活跃的参与者致力于开发 60+ 用于晚期肾细胞癌治疗的管线疗法。
* 领先的晚期肾细胞癌公司，如默沙东、奇泰天庆制药、霍夫曼-罗氏、CoImmune、Infinity Pharmaceuticals、NiKang Therapeutics、Molecure S.A.、Daiichi Sankyo、Janux Therapeutics、MedImmune、礼来公司、江苏恒瑞医药有限公司、同种异体治疗、重庆精准生物科技有限公司、辉瑞、Exelixis、百济神州、Xencor等。
* 有前途的先进肾细胞癌疗法，如 KY1044、JK08、帕博利珠单抗、沙沃替尼、舒尼替尼、TT-10 等。

晚期肾细胞癌：概述

根据美国疾病控制与预防中心 （CDC） 的可信来源，肾细胞癌 （RCC） 是最常见的肾癌类型。这种类型的癌症发生在肾脏内非常小的管子或小管的内壁。这些小管有助于清除血液中的废物。第 4 阶段 RCC 是疾病从肾脏扩散到身体一个或多个远处区域的最晚期阶段。根据 2016 年的一项研究 Trusted Source，晚期 RCC 的前景很大程度上取决于新肿瘤在体内的生长位置。例如，已经扩散到胰腺的 RCC 患者比癌症已经扩散到大脑、骨骼或肝脏的人具有更高的总生存率。

近端肾小管上皮是产生肾细胞癌的肾组织。这两种形式是零星的：非遗传性和遗传性。两种形式的结构改变都发生在 3 号染色体 （3p） 的短臂上。研究了患肾癌的高危家庭，这导致了基因的克隆。改变导致RCC形成的基因是肿瘤抑制基因（VHL，TSC）或致癌基因（MET）。

RCC患者在疾病的早期阶段通常不会出现任何症状。症状可能只会随着疾病的进展而变得明显。ACS Trusted Source 建议人们在出现任何症状时去看医生，例如尿液带血、下背部一侧持续疼痛、侧面或腹部肿块、全身疲劳、不明原因的体重减轻、贫血等。医生可能会建议进行影像学检查以确认癌症并确定癌症是否扩散以及扩散到何种程度。

晚期肾细胞癌很难治愈。然而，肾癌协会 （KCA） 指出，新的治疗方法不断涌现并获得 FDA 的批准。根据 ACS 可信来源，联合或不联合手术的全身治疗是 4 期 RCC 的主要治疗方法。全身治疗可能包括两种免疫治疗药物、一种靶向治疗药物与一种免疫治疗药物，或单独使用一种靶向治疗药物。根据 2021 年的一项研究，免疫治疗药物可以显着改善 RCC 患者的预后。这些药物包括：i）血管内皮生长因子抑制剂（抗VEGF）：这些药物限制了癌症的血液供应。ii） 免疫检查点抑制剂：这些抑制剂有助于人体自身的免疫系统识别和攻击癌细胞。

另一类可能成功治疗 RCC 的药物是酪氨酸激酶抑制剂 （TKI）。这些药物抑制癌细胞生长所需的酶的产生。尽管最近有许多药物被批准用于肾细胞癌（RCC），但仍然迫切需要确定新的治疗靶点。最后，对于特殊患者群体，如体能状态不佳、终末器官功能障碍、脑转移或接受过转移灶切除术的患者，必须考虑其他全身治疗或支持性治疗方法。

DelveInsight 的“晚期肾细胞癌 - 管道洞察，2024 年”报告对整个适应症的现状和增长前景进行了全面的洞察。提供了晚期肾细胞癌管线格局的详细图片，其中包括疾病概述和晚期肾细胞癌治疗指南。报告的评估部分包括对正在开发的管线产品进行深入的晚期肾细胞癌商业评估和临床评估。在报告中，给出了该药物的详细描述，包括药物的作用机制、临床研究、NDA批准（如果有的话）和产品开发活动，包括该技术、晚期肾细胞癌合作、许可、并购、资金、指定和其他产品相关细节。

晚期肾细胞癌的主要参与者

大约有50 +家主要公司正在开发晚期肾细胞癌的治疗方法。晚期肾细胞癌候选药物处于最晚期阶段（即III期）的公司包括默沙东。

只是DelveInsight报告的简介

全部讨论

躺好了
07-05 22:38

Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report
* July 2024:- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
* June 2024:- Bristol-Myers Squibb- A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
* DelveInsight's Advanced Renal Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma treatment.
* The leading Advanced Renal Cell Carcinoma Companies such as Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
* Promising Advanced Renal Cell Carcinoma Therapies such as KY1044, JK08, Pembrolizumab, Savolitinib, Sunitinib, TT-10, and others.
Advanced Renal Cell Carcinoma PipelineDelveInsight’s, “Advanced Renal Cell Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography CoveredGlobal coverage
Advanced Renal Cell Carcinoma: UnderstandingAdvanced Renal Cell Carcinoma: Overview
According to the Centers for Disease Control and Prevention (CDC) Trusted Source, Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. This type of cancer develops in the lining of very small tubes, or tubules, inside the kidney. These tubules help to remove waste products from the blood. Stage 4 RCC is the most advanced stage where the disease has spread from the kidneys to one or more distant areas of the body. According to a 2016 study Trusted Source, the outlook for advanced RCC depends largely on where the new tumors are growing in the body. For example, people with RCC that has spread to the pancreas have a higher overall survival rate than those where cancer has spread to the brain, bones, or liver.
The proximal renal tubular epithelium is the kidney tissue from which RCC arises. The two forms are sporadic: nonhereditary and hereditary. The structural alterations of both forms occur on the short arm of chromosome 3 (3p). Families at high risk for developing renal cancer were studied, which led to the cloning of genes. The genes whose alteration resulted in RCC formation were tumor suppressors (VHL, TSC) or oncogenes (MET).
People with RCC typically do not experience any symptoms during the early stages of the disease. Symptoms may only become apparent as the disease progresses. The ACS Trusted Source advises people to see a doctor if they experience any of the symptoms such as blood in the urine, persistent pain on one side of the lower back, a lump on the side or abdomen, general fatigue, unexplained weight loss, anemia, and others. Doctors may recommend imaging tests to confirm the cancer and determine whether and to what extent it has spread.
Advanced RCC is very difficult to cure. However, the Kidney Cancer Association (KCA) notes that new treatments are continually emerging and gaining FDA approval. According to the ACS Trusted Source, systemic therapy with or without surgery is the mainstay treatment for stage 4 RCC. Systemic therapy may consist of two immunotherapy drugs, a targeted therapy drug with an immunotherapy drug, or a targeted therapy drug alone. According to a 2021 study, immunotherapy drugs can significantly improve outcomes in people with RCC. Such drugs include: i) Vascular endothelial growth factor inhibitors (anti-VEGFs): These restrict the blood supply to the cancer. ii) Immune checkpoint inhibitors: These help the person’s own immune system recognize and attack cancer cells.
Another class of drugs that may successfully treat RCC is tyrosine kinase inhibitors (TKIs). These medications inhibit the production of enzymes that cancer cells require for growth. Despite many recent drug approvals for renal cell cancer (RCC), there remains a pressing must identify new therapeutic targets. Finally, other systemic therapy or supportive care approaches must be considered for special patient populations such as those with poor performance status, end-organ dysfunction, brain metastases, or who have undergone metastasectomy.
"Advanced Renal Cell Carcinoma- Pipeline Insight, 2024" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
对应的原文，自动翻译可能会翻译的不准确，可以参考原文

躺好了
07-05 22:58

被国外专业媒体评价为有前途的疗法还是有点自豪的